Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do a Salesforce stock analysis and discuss the risks and upside potential of CRM stock.

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
22 Oct 2025, 22:41 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a Salesforce stock analysis and discuss the risks and upside potential of CRM stock.
Source overview

AI-generated source summary

Salesforce (CRM) has shown a recent upward trend, breaking out of a prior downtrend. The stock is currently trading around $254.28. The analysis suggests a bullish outlook, with a potential target price of $260.00. A break below $250.00 would invalidate this bullish setup. The company's financial performance, particularly its revenue growth and improving operating margins, are cited as supporting factors. Despite past concerns about share buybacks and stock-based compensation, the current market perception appears to be shifting positively, driven by the company's focus on AI and reaccelerating growth.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail